Literature DB >> 26855637

CANCER MUCOSA ANTIGENS A NOVEL PARADIGM IN CANCER IMMUNOTHERAPEUTICS.

Adam E Snook1, Scott A Waldman1.   

Abstract

Employing antigens with expression restricted to normal intestinal mucosa and derivative colorectal tumors - cancer mucosa antigens (CMAs) - represents a novel paradigm in anti-tumor immunotherapy. Immune compartmentalization limits tolerance to CMAs and restricts mucosa-targeted autoimmunity, allowing safe and effective immunotherapy for metastatic colorectal cancer. Guanylyl cyclase C (GCC), an intestine/colorectal cancer-restricted protein, is poised for clinical evaluation as the index CMA.

Entities:  

Year:  2009        PMID： 26855637      PMCID： PMC4742354     

Source DB:  PubMed          Journal:  Bioforum Eur        ISSN： 1611-597X


  10 in total

1.  Mucosally restricted antigens as novel immunological targets for antitumor therapy.

Authors:  Adam E Snook; Benjamin J Stafford; Laurence C Eisenlohr; Jay L Rothstein; Scott A Waldman
Journal:  Biomark Med       Date:  2007-06       Impact factor: 2.851

Review 2.  Chemokines and the tissue-specific migration of lymphocytes.

Authors:  Eric J Kunkel; Eugene C Butcher
Journal:  Immunity       Date:  2002-01       Impact factor: 31.745

Review 3.  Immunology and immunotherapy of colorectal cancer.

Authors:  Piero Dalerba; Cristina Maccalli; Chiara Casati; Chiara Castelli; Giorgio Parmiani
Journal:  Crit Rev Oncol Hematol       Date:  2003-04       Impact factor: 6.312

4.  Guanylyl cyclase C messenger RNA is a biomarker for recurrent stage II colorectal cancer.

Authors:  B Cagir; A Gelmann; J Park; T Fava; A Tankelevitch; E W Bittner; E J Weaver; J P Palazzo; D Weinberg; R D Fry; S A Waldman
Journal:  Ann Intern Med       Date:  1999-12-07       Impact factor: 25.391

5.  Escherichia coli heat-stable enterotoxin receptors. A novel marker for colorectal tumors.

Authors:  S L Carrithers; S J Parkinson; S D Goldstein; P K Park; R W Urbanski; S A Waldman
Journal:  Dis Colon Rectum       Date:  1996-02       Impact factor: 4.585

6.  Clinical and immunologic responses to active specific cancer vaccines in human colorectal cancer.

Authors:  Dirk Nagorsen; Eckhard Thiel
Journal:  Clin Cancer Res       Date:  2006-05-15       Impact factor: 12.531

7.  Type, density, and location of immune cells within human colorectal tumors predict clinical outcome.

Authors:  Jérôme Galon; Anne Costes; Fatima Sanchez-Cabo; Amos Kirilovsky; Bernhard Mlecnik; Christine Lagorce-Pagès; Marie Tosolini; Matthieu Camus; Anne Berger; Philippe Wind; Franck Zinzindohoué; Patrick Bruneval; Paul-Henri Cugnenc; Zlatko Trajanoski; Wolf-Herman Fridman; Franck Pagès
Journal:  Science       Date:  2006-09-29       Impact factor: 47.728

Review 8.  Cancer statistics, 2004.

Authors:  Ahmedin Jemal; Ram C Tiwari; Taylor Murray; Asma Ghafoor; Alicia Samuels; Elizabeth Ward; Eric J Feuer; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2004 Jan-Feb       Impact factor: 508.702

Review 9.  Cancer mucosa antigens as a novel immunotherapeutic class of tumor-associated antigen.

Authors:  A E Snook; L C Eisenlohr; J L Rothstein; S A Waldman
Journal:  Clin Pharmacol Ther       Date:  2007-09-26       Impact factor: 6.875

10.  Guanylyl cyclase C-induced immunotherapeutic responses opposing tumor metastases without autoimmunity.

Authors:  Adam E Snook; Benjamin J Stafford; Peng Li; Gene Tan; Lan Huang; Ruth Birbe; Stephanie Schulz; Matthias J Schnell; Mathew Thakur; Jay L Rothstein; Laurence C Eisenlohr; Scott A Waldman
Journal:  J Natl Cancer Inst       Date:  2008-06-24       Impact factor: 13.506
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.